Mina K. Chung, MD, is a clinical cardiac electrophysiologist and translational scientist at the Cleveland Clinic. Her overall goal is to bring the basic advances in atrial fibrillation research back to the bedside as soon as possible. She initially studied the inflammatory connections of postoperative atrial fibrillation (AF), producing seminal studies that contributed to interest in upstream therapies for AF. Over a decade ago Dr. Chung founded and began leading a multidisciplinary group at the Cleveland Clinic focused upon the study of genetics and genomics in AF. This group has obtained NIH funding since then to study the genetics of AF, identifying genes and causal genetic variants and leading to new insights for functional and mechanistic studies, again with the aim of bringing these findings back to the patients. Dr. Chung brought in inducible pluripotent stem cell (iPSC) reprogramming and differentiation technologies into her labs, allowing creation of patient-specific cardiomyocyte models for exploring genetic mechanisms of AF. She is also exploring artificial intelligence and big data analyses in cardiovascular medicine using machine learning methodologies.